Study Of Trivanga Bhasma to cure the Madhumehi (Diabetic) Patients

Pharmaceutico- Pharmacological study of Trivanga Bhasma and its efficacy in the management of Madhumeha (Type 2 Diabetes Mellitus)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012361

Enrollment

Registered

2018-03-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: null- Patients having chief and associated complains of Madhumeha (Prabhuta Avilamutrata pipashadhikya kshudhadhikya etc) Known patient of Type 2 Diabetes Mellitus

Interventions

Intervention1: Trivanga Bhasma with Nisha Amalaki Churna : Dose: Trivanga Bhasma 125 mg +Nisha churna 125mg+Amalaki churna125mg one capsule One capsule before meal orally once in morning. Duration

Honey Control Intervention1: Not applicable: Not applicable

Eligibility

Inclusion criteria

Inclusion criteria: 1 Both the sexes having age between 30 to 60 years. 2 Patients having chief & associated complains of Madhumeha (Prabhuta-Avilamutrata, pipashadhikya, kshudhadhikya etc.) 3 Known patient of Type 2 Diabetes Mellitus and also the preliminarily diagnosed patients based on signs and symptoms of the disease are confirmed by FBS and PPBS.

Exclusion criteria

Exclusion criteria: 1 Age more than 60 and below 30 years 2 All patients of diabetes mellitus dependent on insulin. 3 Malignant and accelerated hypertensive. 4 CNS disorder e.g. encephalopathy 5 Other chronic debilitating diseases like STD etc. 6 Pregnant woman and planning to be pregnant within six month 7 Lactating mothers. 8 Secondary Diabetes mellitus 9 Diabetic nephropathy 10 End stage renal disease 11 Non healing Diabetic ulcer (Diabetic foot) 12 Other chronic debilitating diseases.

Design outcomes

Primary

Measure	Time frame
The primary end-point was symptomatic relief, reduction and control of NIDDM symptoms, polydipsia, polyuria, polyphagia, burning sensation in hands and soles, pain/ cramps, fasting and postprandial blood sugar levelsTimepoint: After 3 months trial drugs intervention.	—

Secondary

Measure	Time frame
Trivanga Bhasma safety and toxicity profiles were secondary end points.Timepoint: 18 months	—

Countries

India

Contacts

Public ContactProf B J Patgiri

Institute for Post Graduate Teaching and Research in Ayurveda

patgiri124@gmail.com9426947438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026